Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4/6 inhibitors in breast cancer

Summary: Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) are key therapeutic agents in the management of metastatic hormone-receptor-positive breast cancer. However, the emergence of drug resistance limits their long-term efficacy. Here, we show that breast cancer cells develop CDK4/6i resistan...

全面介紹

書目詳細資料

發表在:	Cell Reports
Main Authors:	Sungsoo Kim, Jessica Armand, Anton Safonov, Mimi Zhang, Rajesh K. Soni, Gary Schwartz, Julia E. McGuinness, Hanina Hibshoosh, Pedram Razavi, Minah Kim, Sarat Chandarlapaty, Hee Won Yang
格式:	Article
語言:	英语
出版:	Elsevier 2023-11-01
主題:	CP: Cancer
在線閱讀:	http://www.sciencedirect.com/science/article/pii/S221112472301210X